tetano
Editor, Senior Moderator
J Infect Dis. (2014) doi: 10.1093/infdis/jiu190 First published online: March 27, 2014
Distinct cross-reactive B-cell responses to live attenuated and inactivated influenza vaccines
Sanae Sasaki1,5,
Tyson H. Holmes2,
Randy A. Albrecht6,
Adolfo Garc?a-Sastre6,7,
Cornelia L. Dekker3,
Xiao-Song He4,5 and
Harry B. Greenberg1,4,5
+ Author Affiliations
1Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305
2Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305
3Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305
4Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305
5VA Palo Alto Health Care System, Palo Alto, CA 94304
6Department of Microbiology and Global Health and Emerging Pathogens Institute
7Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY 10029
Correspondence: Xiao-Song He, VA Medical Center 154C, 3801 Miranda Avenue, Palo Alto, CA 94304. Tel. 650-493-5000 ext. 66135. Fax 650-852-3259. E-mail: xiaosong@stanford.edu.
Abstract
Background. The immunological bases for the efficacies of the two currently licensed influenza vaccines, the live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV), are not fully understood. The goal of this study was to identify specific B-cell responses correlated with the known efficacies of these two vaccines.
Methods. We compared the B-cell and antibody responses after immunization with 2010/2011 IIV versus LAIV in young adults, focusing on peripheral plasmablasts at days 6-8 post-vaccination.
Results. The quantities of vaccine-specific plasmablasts and plasmablast-derived polyclonal antibodies (PPAb) were significantly higher in IIV recipients than in LAIV recipients. No significant difference was detected in the avidity of vaccine-specific PPAb between the two vaccine groups. Proportionally, LAIV induced a greater vaccine-specific IgA plasmablast response as well as a greater plasmablast response to the conserved influenza nuclear protein than did IIV. The cross-reactive plasmablast response to heterovariant strains, as indicated by the relative levels of cross-reactive plasmablasts and the cross-reactive PPAb binding reactivity, was also greater in the LAIV group.
Conclusions. Distinct quantitative and qualitative patterns of plasmablast responses were induced by LAIV and IIV in young adults; a proportionally greater cross-reactive response was induced by LAIV.
http://jid.oxfordjournals.org/content/early/2014/03/26/infdis.jiu190.abstract
Distinct cross-reactive B-cell responses to live attenuated and inactivated influenza vaccines
Sanae Sasaki1,5,
Tyson H. Holmes2,
Randy A. Albrecht6,
Adolfo Garc?a-Sastre6,7,
Cornelia L. Dekker3,
Xiao-Song He4,5 and
Harry B. Greenberg1,4,5
+ Author Affiliations
1Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305
2Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305
3Department of Pediatrics, Stanford University School of Medicine, Stanford, CA 94305
4Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305
5VA Palo Alto Health Care System, Palo Alto, CA 94304
6Department of Microbiology and Global Health and Emerging Pathogens Institute
7Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY 10029
Correspondence: Xiao-Song He, VA Medical Center 154C, 3801 Miranda Avenue, Palo Alto, CA 94304. Tel. 650-493-5000 ext. 66135. Fax 650-852-3259. E-mail: xiaosong@stanford.edu.
Abstract
Background. The immunological bases for the efficacies of the two currently licensed influenza vaccines, the live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV), are not fully understood. The goal of this study was to identify specific B-cell responses correlated with the known efficacies of these two vaccines.
Methods. We compared the B-cell and antibody responses after immunization with 2010/2011 IIV versus LAIV in young adults, focusing on peripheral plasmablasts at days 6-8 post-vaccination.
Results. The quantities of vaccine-specific plasmablasts and plasmablast-derived polyclonal antibodies (PPAb) were significantly higher in IIV recipients than in LAIV recipients. No significant difference was detected in the avidity of vaccine-specific PPAb between the two vaccine groups. Proportionally, LAIV induced a greater vaccine-specific IgA plasmablast response as well as a greater plasmablast response to the conserved influenza nuclear protein than did IIV. The cross-reactive plasmablast response to heterovariant strains, as indicated by the relative levels of cross-reactive plasmablasts and the cross-reactive PPAb binding reactivity, was also greater in the LAIV group.
Conclusions. Distinct quantitative and qualitative patterns of plasmablast responses were induced by LAIV and IIV in young adults; a proportionally greater cross-reactive response was induced by LAIV.
http://jid.oxfordjournals.org/content/early/2014/03/26/infdis.jiu190.abstract